- Home
- TYG vs QURE Comparison
TYG vs QURE Comparison
Compare TYG & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TYG | QURE |
|---|---|---|
| Founded | 2003 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2003 | 2013 |
Fundamental Metrics
Financial Performance| Metric | TYG | QURE |
|---|---|---|
| Price | $46.44 | $26.64 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | 83.6K | ★ 1.6M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | ★ 11.71% | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | N/A | $126.12 |
| Revenue Next Year | N/A | $200.43 |
| P/E Ratio | $52.62 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $39.93 | $8.73 |
| 52 Week High | $51.18 | $71.50 |
Technical Indicators
Market Signals| Indicator | TYG | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 37.39 | 76.81 |
| Support Level | $42.25 | $22.59 |
| Resistance Level | $48.99 | $28.63 |
| Average True Range (ATR) | 0.91 | 1.80 |
| MACD | -0.10 | 0.89 |
| Stochastic Oscillator | 1.63 | 80.84 |
Price Performance
Historical ComparisonAbout TYG Tortoise Energy Infrastructure Corporation
Tortoise Energy Infrastructure Corp seeks to provide a high level of current income to stockholders. It invests in fixed-income and dividend-paying equity securities of power and energy infrastructure companies that provide stable and defensive characteristics throughout economic cycles.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.